Jellagen Announces Seed Financing to Develop Advanced Collagen Products for Therapeutic and Medical Device Applications
Jellagen, a leader in advanced collagen biomaterials from marine sources, announces the closing of a £1.9m seed equity round to pursue development of products for therapeutic and medical device applications. The round, which was 75% funded by international investors, will enable Jellagen to develop and partner pipeline products aimed at tissue reconstruction, diabetic wound care management and rare skin applications.
Collagen is the most abundant protein in the human body and is critical for healthy cell function and healing as well as providing key structural component for bones, muscles, skin, and tendons. In the medical field, collagen is used in a range of procedures including tissue reconstruction and wound management. Scientists also use collagen in routine cell culture applications as it provides a natural scaffold for cells to grow under conditions like those found within the human body. Collagen is also used in a variety of food and cosmetic products.
For most applications, collagen is processed from mammalian sources including pigs, cows and rats which carry the risk of disease and virus transfer when used in humans. Jellagen sources its collagen from a single species of jellyfish which not only avoids these risks but also delivers superior healing benefits in human applications. Jellagen has established development collaborations with top research organisations in the US and Europe to investigate and confirm these findings and recent data supporting the advantages of marine collagen have been published in peer-reviewed scientific research articles.
Jellagen was founded in 2015 and has already established a range of products for the cell culture reagent market. After five years of intensive research including collaborations with top institutions in the US and Europe, the Company has completed a pre-clinical data set in proven animal models used to support the use of marine collagen in humans, including tissue reconstruction, diabetic wound healing and other medical applications. The Company will use these to explore development and licensing arrangements with potential pharma and medical device companies with established market positions in these applications.
Thomas-Paul Descamps, CEO of Jellagen, commented:
“While Jellagen was founded on early scientific observations regarding the benefits of marine collagen over the prevalent mammalian sources, we have now compiled a strong pre-clinical data base which demonstrates the advantages in several important medical applications. Our findings have been confirmed through collaborations with leading research and medical institutions in the US and Europe. Our plan now is to find development partners who can help deliver the remarkable benefits of marine collagen to patients in need of advanced biomaterials for tissue reconstruction, wound healing and rare skin applications.”
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VentureIsrael Launches New Venture Capital Fund28.10.2020 01:08:00 CET | Press release
VentureIsrael announced today the launch of a new venture capital fund, which will invest in Israel based, early stage deep-tech start-ups. The fund investment strategy focuses on the companies with clear-cut technological advantages, an experienced management team and a flexible business strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027006270/en/ VentureIsrael Early Stage Deep Tech Fund (Graphic: Business Wire) The fund first investments are a secure quantum communications system, an AI market research solution and a next-generation correspondent banking platform. VentureIsrael is managed by five partners – all investment experts with diverse backgrounds: Michael Harte - former COO of Santander UK and Barclays; Roman Gold, Gadi Isaev and Alexander Zarankin of JSCapital – the Israeli investment platform; and Igor Turkin of Investment Management Group. “The Israeli innovation industry is demonstrating phenomenal
State-of-the-art Photography Results and Immersive AR Experiences: Infineon and pmd Offer 3D-imager With Longest Range in the Market27.10.2020 21:22:00 CET | Press release
Gaming, virtual e-Commerce, 3D online education: Augmented Reality (AR) applications with three-dimensional depth sensors link the real with the digital world and are strongly demanded. Infineon Technologies AG (FSE: IFX / OTCQX: IFNNY) and pmdtechnologies developed a 3D depth sensor based on the Time of Flight (ToF)-technology which outperforms other solutions in the market and aims for target applications that offer a wider spectrum of innovative consumer usability. The 3D sensor market in smartphones for rear side cameras is expected to grow up to more than 500 million units per year until 2024. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027006197/en/ The new REAL3 ToF chip enables better photography results with a faster autofocus in low-light conditions or perfect night mode portraits based on picture segmentation. (Photo: Business Wire) “The latest 3D image sensor from Infineon and pmdtechnologies enables a new
IFF to Release Third Quarter 2020 Results November 927.10.2020 21:15:00 CET | Press release
Regulatory News: IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), a leading innovator of taste, scent, and nutrition, announced that it will release its third quarter 2020 earnings results following the market close on Monday, November 9, 2020. The management team will host a live webcast on Tuesday, November 10, 2020 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE:IFF) (Euronext Paris: IFF) (TASE: IFF), we’re using Uncommon Sense to create what the world needs. As a collective of unconventional thinkers and creators, we put science and artistry to work to create unique and unexpected scents, tastes, experiences and ingredients for the products our world craves. Learn more at iff.com, Twitter , Facebook, Instagram, a
Panasonic: Verifiering av den hämmande effekten hos nanoe™ X, en teknik som nyttjar fördelarna med hydroxylradikaler, på det nya coronaviruset (SARS-CoV-2)27.10.2020 18:30:00 CET | Pressmeddelande
Panasonic tillkännagav idag, i samarbete med den globala kontraktforskningsorganisationen Texcell*1, att Texcell har verifierat den hämmande effekten hos nanoe™ X, en teknik som nyttjar fördelarna med hydroxylradikaler, på det det nya coronaviruset (SARS-CoV-2). nanoe™ X, en joniserare som genererar ”atomiserade vattenpartiklar av nanostorlek”, har utvecklas av Panasonic. Detta är en elektrostatisk atomiseringsteknik som samlar upp osynlig fukt i luften och tillför högspänning för att producera ”hydroxylradikaler i vattnet”. Den avgörande faktorn är att det förekommer hydroxylradikaler i nanoe™ X. Hydroxylradikalerna kännetecknas av att ha en hög oxidation och reaktivitet. Panasonic har bedrivit forskning på denna teknik sedan 1997 och har verifierat dess effektivitet på olika områden, inklusive hämning av vissa patogena mikroorganismer (bakterier, svampar och virus) och allergener, och att den bryter ned PM 2.5-komponenter som har negativa effekter på människokroppen*2. 2012 genomförd
VALBIOTIS Presents the First Market Data on Untreated LDL-hypercholesterolemia For TOTUM-070, And Announces the Initiation of The Phase II Clinical Study HEART27.10.2020 17:40:00 CET | Press release
Regulatory News: VALBIOTIS (Paris:ALVAL) (FR0013254851 – ALVAL / eligible for the PEA/SME), a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, presents the target market for its active substance TOTUM-070, for untreated mild to moderate LDL-hypercholesterolemia. The Phase II clinical study has been initiated and will begin as soon as authorizations are received from the French National Agency for the Safety of Medicines and Health Products (ANSM) and the French Committee for the Protection of Persons (CPP). TOTUM-070 is an innovative active substance derived from food plant extracts, without phytosterols nor red yeast rice, developed to act on lipid metabolism in individuals with hypercholesterolemia. Once development is complete, this new Health Nutrition product will be positioned mainly for people with LDL-hypercholesterolemia, at levels up to 190 mg/dL, with a moderate overall cardiovascular risk. TOTUM-070 could be
Pulse Electronics Switches to Rimini Street Support for its SAP Applications27.10.2020 17:00:00 CET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, today announced that Pulse Electronics, a leading components manufacturer for the automotive and telecommunications industries, has switched to Rimini Street support for its SAP ECC 6.0 and Business Objects software. With the savings achieved by switching support providers, Pulse was able to divert its liberated funding to invest in business intelligence (BI) capabilities including artificial intelligence (AI) technologies to enable growth and competitive advantage during a year when new spending may not have otherwise been possible. The company was also able to defer an expensive forced migration to S/4HANA, required to remain in full support with the vendor, and instead has taken complete control of its IT roadmap to support the businesses’ objectives versus the vendor’s dictated roa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom